Skip to main content

Neurology and Therapy

Ausgabe 1/2021

Inhalt (28 Artikel)

Open Access Commentary

Lennox–Gastaut Syndrome: Perspective of a Parent and a Physician

Heather R. McKee, Barbara Glasgow

Open Access Commentary

Globus Pallidus Internus (GPi) Deep Brain Stimulation for Parkinson’s Disease: Expert Review and Commentary

Ka Loong Kelvin Au, Joshua K. Wong, Takashi Tsuboi, Robert S. Eisinger, Kathryn Moore, Janine Lemos Melo Lobo Jofili Lopes, Marshall T. Holland, Vanessa M. Holanda, Zhongxing Peng-Chen, Addie Patterson, Kelly D. Foote, Adolfo Ramirez-Zamora, Michael S. Okun, Leonardo Almeida

Open Access Review

Targeting of the Subthalamic Nucleus in Patients with Parkinson’s Disease Undergoing Deep Brain Stimulation Surgery

Pepijn van den Munckhof, Maarten Bot, P. Richard Schuurman

Open Access Review

Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms—A Narrative Review

Lynsey Lakin, Bryan E. Davis, Cherie C. Binns, Keisha M. Currie, Mary R. Rensel

Open Access Review

Patient and Provider Insights into the Impact of Multiple Sclerosis on Mental Health: A Narrative Review

Bryan E. Davis, Lynsey Lakin, Cherie C. Binns, Keisha M. Currie, Mary R. Rensel

Open Access Original Research

Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study

Preeya J. Patel, Christian Weidenfeller, Andrew P. Jones, Jens Nilsson, Jay Hsu

Open Access Original Research

Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis

J. Bradford Rice, Mary P. Panaccio, Alan White, Mark Simes, Emma Billmyer, Nathaniel Downes, John Niewoehner, George J. Wan

Open Access Original Research

Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND

Pavle Repovic, Derrick Robertson, Kiren Kresa-Reahl, Stanley L. Cohan, Ray Su, Robin Avila, Irene Koulinska, Jason P. Mendoza

Open Access Original Research

Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis

Edward E. Neuberger, Ibrahim M. Abbass, Eddie Jones, Natalie J. Engmann

Open Access Original Research

Parent Experiences of Sanfilippo Syndrome Impact and Unmet Treatment Needs: A Qualitative Assessment

Katherine Ackerman Porter, Cara O’Neill, Elise Drake, Samantha Parker, Maria L. Escolar, Stacey Montgomery, William Moon, Carolyn Worrall, Holly L. Peay

Open Access Original Research

Quantifying Knowledge of Alzheimer’s Disease: An Analysis of the Psychometric Properties of the Alzheimer’s Disease Knowledge Scale

Guillermo Garcia-Ribas, Elena García-Arcelay, Alonso Montoya, Jorge Maurino, Javier Ballesteros

Open Access Original Research

Recognition of Facial Emotion Expressions in Patients with Depressive Disorders: A Prospective, Observational Study

Roman Vitalievich Akhapkin, Beatrisa Albertovna Volel, Rodion Mikhailovich Shishorin, Dmitry Vladimirovich Ustyuzhanin, Dmitry Sergeevich Petelin

Open Access Original Research

Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials

Susan Hutchinson, David W. Dodick, Christina Treppendahl, Nathan L. Bennett, Sung Yun Yu, Hua Guo, Joel M. Trugman

Open Access Original Research

Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach

Sarah White, Colleen Harris, Michelle Allan, Carol Chieffe, Piet Eelen, Claudia Röder, Catherine Mouzawak, Maria L. Naylor

Open Access Original Research

Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study

Yoshihisa Tatsuoka, Takao Takeshima, Akichika Ozeki, Taka Matsumura

Open Access COVID-19 Original Research

The COVID-19 Pandemic Experience in Multiple Sclerosis: The Good, the Bad and the Neutral

Hannah Morris-Bankole, Aileen K. Ho

Open Access Original Research

Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers

Elizabeth Faust, Irina Pivneva, Karen Yang, Keith A. Betts, Zubair Ahmed, Shivang Joshi, Rebecca Hogan, Andrew Blumenfeld, Jack Schim, Alexander Feoktistov, Kenneth Carnes, Mark Bensink, Eric Q. Wu, Denise E. Chou, David Chandler

Open Access Original Research

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia

Shyamal H. Mehta, Rajesh Pahwa, Caroline M. Tanner, Robert A. Hauser, Reed Johnson

Open Access Original Research

STO: Stroke Ontology for Accelerating Translational Stroke Research

Mahdi Habibi-koolaee, Leila Shahmoradi, Sharareh R. Niakan Kalhori, Hossein Ghannadan, Erfan Younesi

Open Access Original Research

The Association Between Dietary Acid Load and Odds of Migraine: A Case–Control Survey

Maryam Mousavi, Soodeh Razeghi Jahromi, Mansoureh Togha, Zeinab Ghorbani, Azita Hekmatdoost, Pegah Rafiee, Boshra Torkan, Pedram Shirani, Hossein Ansari, Ahmadreza Karami, Morvarid Nourmohammadi, Faezeh Khorsha

Open Access Brief Report

Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence

Jacob Liseno, Brittney Lager, Catherine Miller, Sai L. Shankar, Jason P. Mendoza, James B. Lewin

Open Access Study Protocol

Design of a Non-Interventional Study to Validate a Set of Patient- and Caregiver-Oriented Measurements to Assess Health Outcomes in Spinal Muscular Atrophy (SMA-TOOL Study)

Marcos Madruga-Garrido, Juan F. Vázquez-Costa, Julita Medina-Cantillo, María Brañas, María G. Cattinari, Mencía de Lemus, Paola Díaz-Abós, Victoria Sánchez-Menéndez, Ángeles Terrancle, Pablo Rebollo, Jorge Maurino

Open Access Study Protocol

Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Teresa Coelho, Yukio Ando, Merrill D. Benson, John L. Berk, Márcia Waddington-Cruz, Peter J. Dyck, Julian D. Gillmore, Sami L. Khella, William J. Litchy, Laura Obici, Cecilia Monteiro, Li-Jung Tai, Nicholas J. Viney, Gustavo Buchele, Michela Brambatti, Shiangtung W. Jung, Louis St. L. O’Dea, Sotirios Tsimikas, Eugene Schneider, Richard S. Geary, Brett P. Monia, Morie Gertz

Open Access Practical Approach

Evidence-Based Recommendations for the Oral Health of Patients with Parkinson’s Disease

Ana L. C. Martimbianco, Fabio C. Prosdocimi, Camillo Anauate-Netto, Elaine M. dos Santos, Gustavo D. Mendes, Yara D. Fragoso

Open Access Case Report

Rivaroxaban in Recurrent Ischemic Stroke Due to Protein S Deficiency: A Case Report

Saba Naghavi, Ahmad Pourmohammadi, Iman Adibi

Open Access Correction

Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis

Ivan Urits, Daniel Swanson, Michael C. Swett, Anjana Patel, Kevin Berardino, Ariunzaya Amgalan, Amnon A. Berger, Hisham Kassem, Alan D. Kaye, Omar Viswanath

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.